Wells Fargo upgrades Zimmer Biomet to Overweight, lifts price target to $123

Wells Fargo raised its rating on Zimmer Biomet to Overweight and increased its price target to $123, up from $113. The upgrade cites the upcoming launch of the Monogram orthopedic robot, expected in the first half of 2027, and the system’s acquisition for $177 million in 2025. The firm also noted the company’s third‑quarter revenue of $2.06 billion and organic revenue growth of 3.7%.

The higher rating and price target suggest a potential upside for investors, while the Monogram launch could boost future earnings. The upgrade may also influence other analysts’ estimates and market sentiment toward ZBH.

  • 1Wells Fargo upgraded Zimmer Biomet to Overweight from Equal Weight.
  • 2The price target was raised to $123 from $113.
  • 3Wells Fargo expects the Monogram robot to launch in the first half of 2027.
  • 4Zimmer Biomet acquired the Monogram robot in a $177 million deal in 2025.
  • 5Third‑quarter revenue was $2.06 billion.
  • 6Organic revenue growth accelerated to 3.7% in the quarter.

Sources